Vincent Trudeau1,2, Alessandro Larcher3,4, Maxine Sun3, Katharina Boehm3,5, Paolo Dell'Oglio3,4, José Sosa3, Zhe Tian3,6, Nicola Fossati4, Alberto Briganti4, Shahrokh F Shariat7, Pierre I Karakiewicz3,8. 1. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, 264 Blvd. Rene-Levesque E. Room 228, Montreal, QC, H2X 1P1, Canada. vincent.trudeau.1@umontreal.ca. 2. Department of Urology, University of Montreal Health Center, Montreal, Canada. vincent.trudeau.1@umontreal.ca. 3. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, 264 Blvd. Rene-Levesque E. Room 228, Montreal, QC, H2X 1P1, Canada. 4. Division of Oncology, Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. 5. Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany. 6. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada. 7. Department of Urology, Medical University of Vienna, Vienna, Austria. 8. Department of Urology, University of Montreal Health Center, Montreal, Canada.
Abstract
BACKGROUND: Sarcomatoid renal cell carcinoma (sRCC) is a rare histological subtype that is associated with unfavorable prognosis. We sought to examine the effect of sRCC on cancer-specific mortality (CSM) relative to clear cell renal cell carcinoma (ccRCC), after adjusting for other variables, as well as other-cause mortality (OCM). METHODS: We relied on the Surveillance, Epidemiology, and End Results-Medicare database from 2000 to 2009 to identify a cohort of 7916 patients with either sRCC (n = 234) or ccRCC (n = 7682) who received surgery as primary treatment. Patient, tumor, and treatment characteristics were evaluated. Then, 5-year smoothed Poisson regression CSM and OCM estimates were generated for stage-by-stage comparisons between sRCC and ccRCC. A multivariable competing-risks regression model predicting CSM and adjusting for several patient and tumor characteristics, as well as OCM, was finally fitted. RESULTS: Compared to ccRCC patients, sRCC patients had more advanced and more aggressive disease at diagnosis. Specifically, 48 and 7 % of sRCC and ccRCC patients presented with stage IV disease, respectively (p < 0.001). Overall, 5-year CSM and OCM estimates were 67 and 17 % for sRCC patients and 14 and 19 % for ccRCC patients. In stage-by-stage analyses, sRCC was invariably associated with worse CSM. After adjusting for several characteristics as well as OCM, sRCC was associated with a 3.2 higher risk of CSM compared with ccRCC. CONCLUSIONS: Patients with sRCC are present with more advanced disease. Moreover, sRCC is associated with a higher rate of CSM, even after adjusting for several characteristics and OCM.
BACKGROUND:Sarcomatoid renal cell carcinoma (sRCC) is a rare histological subtype that is associated with unfavorable prognosis. We sought to examine the effect of sRCC on cancer-specific mortality (CSM) relative to clear cell renal cell carcinoma (ccRCC), after adjusting for other variables, as well as other-cause mortality (OCM). METHODS: We relied on the Surveillance, Epidemiology, and End Results-Medicare database from 2000 to 2009 to identify a cohort of 7916 patients with either sRCC (n = 234) or ccRCC (n = 7682) who received surgery as primary treatment. Patient, tumor, and treatment characteristics were evaluated. Then, 5-year smoothed Poisson regression CSM and OCM estimates were generated for stage-by-stage comparisons between sRCC and ccRCC. A multivariable competing-risks regression model predicting CSM and adjusting for several patient and tumor characteristics, as well as OCM, was finally fitted. RESULTS: Compared to ccRCC patients, sRCC patients had more advanced and more aggressive disease at diagnosis. Specifically, 48 and 7 % of sRCC and ccRCC patients presented with stage IV disease, respectively (p < 0.001). Overall, 5-year CSM and OCM estimates were 67 and 17 % for sRCC patients and 14 and 19 % for ccRCC patients. In stage-by-stage analyses, sRCC was invariably associated with worse CSM. After adjusting for several characteristics as well as OCM, sRCC was associated with a 3.2 higher risk of CSM compared with ccRCC. CONCLUSIONS:Patients with sRCC are present with more advanced disease. Moreover, sRCC is associated with a higher rate of CSM, even after adjusting for several characteristics and OCM.
Authors: Badar M Mian; Nishin Bhadkamkar; Joel W Slaton; Peter W T Pisters; Danai Daliani; David A Swanson; Louis L Pisters Journal: J Urol Date: 2002-01 Impact factor: 7.450
Authors: Christos E Kyriakopoulos; Namita Chittoria; Toni K Choueiri; Nils Kroeger; Jae-Lyun Lee; Sandy Srinivas; Jennifer J Knox; Georg A Bjarnason; Scott D Ernst; Lori A Wood; Ulka N Vaishampayan; Neeraj Agarwal; Sumanta K Pal; Ravindran Kanesvaran; Sun-Young Rha; Takeshi Yuasa; Frede Donskov; Scott A North; Daniel Y Heng; Brian I Rini Journal: Clin Genitourin Cancer Date: 2014-09-23 Impact factor: 2.872
Authors: M de Peralta-Venturina; H Moch; M Amin; P Tamboli; S Hailemariam; M Mihatsch; J Javidan; H Stricker; J Y Ro; M B Amin Journal: Am J Surg Pathol Date: 2001-03 Impact factor: 6.394
Authors: Maxine Sun; Firas Abdollah; Daniel Liberman; Al'a Abdo; Rodolphe Thuret; Zhe Tian; Shahrokh F Shariat; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Cancer Date: 2011-03-08 Impact factor: 6.860
Authors: Kirk A Keegan; Clayton W Schupp; Karim Chamie; Nicholas J Hellenthal; Christopher P Evans; Theresa M Koppie Journal: J Urol Date: 2012-06-13 Impact factor: 7.450
Authors: Maxine Sun; Giovanni Lughezzani; Claudio Jeldres; Hendrik Isbarn; Shahrokh F Shariat; Philippe Arjane; Hugues Widmer; Daniel Pharand; Mathieu Latour; Paul Perrotte; Jean-Jacques Patard; Pierre I Karakiewicz Journal: Eur Urol Date: 2009-06-21 Impact factor: 20.096
Authors: Ben Y Zhang; R Houston Thompson; Christine M Lohse; Bradley C Leibovich; Stephen A Boorjian; John C Cheville; Brian A Costello Journal: BJU Int Date: 2014-10-19 Impact factor: 5.588
Authors: David C Miller; Christopher S Saigal; Joan L Warren; Meryl Leventhal; Dennis Deapen; Mousumi Banerjee; Julie Lai; Jan Hanley; Mark S Litwin Journal: BMC Health Serv Res Date: 2009-06-06 Impact factor: 2.655
Authors: Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki Journal: World J Urol Date: 2018-06-01 Impact factor: 4.226
Authors: Abhishek Maiti; Maryam Nemati-Shafaee; Pavlos Msaouel; Lance C Pagliaro; Eric Jonasch; Nizar M Tannir; Amishi Y Shah Journal: Clin Genitourin Cancer Date: 2017-08-10 Impact factor: 2.872
Authors: Jose A Karam; A Ari Hakimi; Kyle A Blum; Sounak Gupta; Satish K Tickoo; Timothy A Chan; Paul Russo; Robert J Motzer Journal: Nat Rev Urol Date: 2020-10-13 Impact factor: 14.432